Preclinical
October 12, 2023
AACR-EORTC-NCI
Refining our understanding of ADCs: Drug development insights from 40 years of data
Raffaele Colombo
Preclinical
October 10, 2023
Festival of Biologics
TOPO1i ADC Platform From Concept to Pipeline Application
Mark Petersen
Preclinical
October 2, 2023
World Bispecific Summit
Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors
Nina Weisser
Preclinical
June 12, 2023
Journal of Medicinal Chemistry
Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads
Petersen et al.
Preclinical
June 2, 2023
Bioorganic & Medicinal Chemistry Letters
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates
Brant et al.
Preclinical
May 15, 2023 - May 19, 2023
PEGS
Optimization of purine-based TLR7 agonists as payloads for immune-stimulating antibody conjugates (ISACs)
Garnett et al.
Preclinical
May 19, 2023
PEGS
Engineering and Preclinical Development of ZW171: A 2+1 Format Anti-MSLN T Cell Engager
Piscitelli et al.
Preclinical
May 15, 2023 - May 19, 2023
PEGS
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Bhoiane et al.
Preclinical
May 10, 2023
STING & TLR-Targeting Therapies Summit
Evaluation of TLR7-agonists as payloads for immune-stimulating antibody conjugates
Graham Garnett
Preclinical
April 18, 2023
AACR
TriTCE Co-Stim, Next Generation Co-Stimulatory Trispecific T cell Engagers for the Treatment of Solid Tumors
Newhook et al.
Preclinical
April 17, 2023
AACR
PROTECT™, A Novel Trispecific Antibody Masking Platform With Integrated Immune Modulation Displays Unique Activity and Differentiated Modes of Action
Von Rossum et al.
Preclinical
April 17, 2023
AACR
ZW251, a novel Glypican 3-targeting antibody drug conjugate bearing a topoisomerase I inhibitor payload
Madera et al.
